<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04937920</url>
  </required_header>
  <id_info>
    <org_study_id>DBI-202</org_study_id>
    <nct_id>NCT04937920</nct_id>
  </id_info>
  <brief_title>A Trial to Evaluate the Safety and Antimicrobial Efficacy of DBI-002 Probiotic in Adults With Tinea Versicolor</brief_title>
  <official_title>A Randomized, Double-Blinded, Aqueous Gel-Controlled Dose Escalating Trial to Study the Safety and Antimicrobial Efficacy of DBI-002 Probiotic vs. Aqueous Gel and Vehicle Gel vs. Aqueous Gel in Adults With Tinea Versicolor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DermBiont, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>DermBiont, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized, Double-Blinded, Aqueous Gel-Controlled Dose Escalating Trial to Study the&#xD;
      Safety and Antimicrobial Efficacy of DBI-002 Probiotic vs. Aqueous Gel and Vehicle Gel vs.&#xD;
      Aqueous Gel in Adults with Tinea Versicolor (DBI-202).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 16, 2021</start_date>
  <completion_date type="Anticipated">November 12, 2021</completion_date>
  <primary_completion_date type="Actual">September 20, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events</measure>
    <time_frame>14 days of participation</time_frame>
    <description>Safety</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Molecular diagnostic qPCR comparison of DBI-002 Drug Product and Malassezia (fungal cause of tinea versicolor)</measure>
    <time_frame>14 days of participation</time_frame>
    <description>Antimicrobial Efficacy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with decrease in signs and symptoms of tinea versicolor for the DBI-002 DP-treated lesion compared to the aqueous gel treated lesion</measure>
    <time_frame>14 days of participation</time_frame>
    <description>Clinical efficacy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Tinea Versicolor</condition>
  <arm_group>
    <arm_group_label>DBI-002 probiotic gel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topical application of DBI-002 probiotic gel on skin affected with tinea versicolor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aqueous gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Topical application of aqueous gel on skin affected with tinea versicolor</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DBI-002 probiotic gel</intervention_name>
    <description>Topical application on skin affected with tinea versicolor</description>
    <arm_group_label>DBI-002 probiotic gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Aqueous gel</intervention_name>
    <description>Topical application on skin affected with tinea versicolor</description>
    <arm_group_label>Aqueous gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ability to understand, agree to and sign the study Informed Consent Form (ICF). If the&#xD;
             subject is unable to provide consent him/herself, the subject's legally acceptable&#xD;
             representative may provide written consent.&#xD;
&#xD;
          2. Male or Female Subjects of any race 18 - 65 years of age.&#xD;
&#xD;
          3. Subjects with a clinical diagnosis of Tinea versicolor (TV is a common benign&#xD;
             superficial cutaneous fungal infection usually characterized by hypopigmented or&#xD;
             hyperpigmented macules and patches on the chest and back).&#xD;
&#xD;
          4. A positive potassium hydroxide (KOH) examination consistent with Malassezia prior to&#xD;
             the treatment period done at the clinical site.&#xD;
&#xD;
          5. Agree to not use soap and water on the chest and back for at least 12 hours before the&#xD;
             study visits for Baseline/Day 1, Day 5, and Day 14, and follow all study instructions&#xD;
             for use of soap and water on the chest and back during participation in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Females who are pregnant, planning a pregnancy, or breastfeeding.&#xD;
&#xD;
          2. Any dermatological conditions that could interfere with clinical evaluations or any&#xD;
             disease state or physical condition which might expose the patient to an unacceptable&#xD;
             risk by study participation.&#xD;
&#xD;
          3. Any underlying disease(s) or other dermatological conditions that require the use of&#xD;
             exclusionary topical or systemic therapy (see below).&#xD;
&#xD;
          4. Known sensitivity to any of the components of the study medication.&#xD;
&#xD;
          5. Use of a prescription or non-prescription topical treatment on the targeted TV&#xD;
             anatomical locations within the previous 4 weeks, for example: anti-fungal,&#xD;
             antibacterial or anti-microbial products, selenium and anti-inflammatories (e.g.,&#xD;
             corticosteroids).&#xD;
&#xD;
          6. Use of a systemic anti-fungal or antibiotic treatment for TV within the previous 4&#xD;
             weeks, Use of medicated shampoos and/or soaps within the previous 4 weeks.&#xD;
&#xD;
          7. Treatment of any type of cancer within the last 6 months.&#xD;
&#xD;
          8. History of any significant internal disease which contraindicates use of live&#xD;
             microbiome (e.g. leukemia, liver failure, cardiovascular disease).&#xD;
&#xD;
          9. Subjects who are known to be allergic to any of the test product(s) or any components&#xD;
             in the investigational product(s) or history of hypersensitivity or allergic reactions&#xD;
             to any of the study preparations as described in the Investigator's Brochure (IB).&#xD;
&#xD;
         10. AIDS or AIDS related complex by medical history.&#xD;
&#xD;
         11. Known or suspected use of immunosuppressive medications and/or has a known or&#xD;
             suspected autoimmune disease.&#xD;
&#xD;
         12. Any subject not able to meet the study attendance requirements.&#xD;
&#xD;
         13. Subjects who have participated in any other trial of an investigational drug or device&#xD;
             within 30 days prior to enrollment or participation in a research study concurrent&#xD;
             with this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Zepeda, MD</last_name>
    <role>Study Director</role>
    <affiliation>Zepeda Dermatologia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zepeda Dermatologia</name>
      <address>
        <city>Santa Tecla</city>
        <state>La Libertad</state>
        <country>El Salvador</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>El Salvador</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 1, 2021</study_first_submitted>
  <study_first_submitted_qc>June 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tinea</mesh_term>
    <mesh_term>Tinea Versicolor</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

